<DOC>
	<DOCNO>NCT00532129</DOCNO>
	<brief_summary>This single arm study assess safety effect response rate combination rituximab chlorambucil previously untreated participant B-cell chronic lymphocytic leukemia . Participants receive 6 monthly cycle combination treatment , follow 6 cycle chlorambucil alone . Rituximab administer Day 1 cycle , dose 375 milligram per square meter ( mg/m^2 ) intravenously ( IV ) Cycle 1 , 500 mg/m^2 subsequent cycle , chlorambucil administer Days 1-7 cycle dose 10 mg/m^2/day per oral ( PO ) .</brief_summary>
	<brief_title>A Study MabThera ( Rituximab ) Plus Chlorambucil Participants With Chronic Lymphocytic Leukemia .</brief_title>
	<detailed_description />
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<mesh_term>Chlorambucil</mesh_term>
	<criteria>previously untreated participant cluster differentiation 20 ( CD20 ) positive Bcell chronic lymphocytic leukemia ; participant progressive Binet stage B , C require therapy accord National Cancer Institute ( NCI ) criteria ; Eastern Cooperative Oncology Group ( ECOG ) performance status &lt; =2 . previous treatment Chronic Lymphocytic Leukaemia ( CLL ) ; know concomitant hematological malignancy ; transformation aggressive Bcell malignancy ; history severe cardiac disease ; know hypersensitivity anaphylactic reaction murine antibody .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>